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Abstract
X-adrenoleukodystrophy (X-ALD) is a complex disease where inactivation of ABCD1 gene
results in clinically diverse phenotypes, the fatal disorder of cerebral ALD (cALD) or a milder
disorder of adrenomyeloneuropathy (AMN). Loss of ABCD1 function results in defective beta
oxidation of very long chain fatty acids (VLCFA) resulting in excessive accumulation of VLCFA,
the biochemical “hall mark” of X-ALD. At present, the ABCD1-mediated mechanisms that
determine the different phenotype of X-ALD are not well understood. The studies reviewed here
suggest for a “three-hit hypothesis” for neuropathology of cALD. An improved understanding of
the molecular mechanisms associated with these three phases of cALD disease should facilitate
the development of effective pharmacological therapeutics for X-ALD.
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Introduction
With an incidence of 1 in 17 000 males, X-linked adrenoleukodystrophy (X-ALD, OMIM
number 300100) is the most common monogenic leukodystrophy and peroxisomal disorder.
It is characterized by axonopathy in the spinal cord, demyelination in the cerebral
hemispheres and adrenal insufficiency. X-ALD patients accumulate saturated, and to a lesser
extent, monounsaturated, very long chain fatty acids (VLCFA) in plasma and tissues, most
notably in the brain and adrenal cortex (14,40,59).
All X-ALD patients present with mutations in the ABCD1 gene, which encodes a
peroxisomal adenosin triphosphate (ATP)-binding cassette transporter protein (ABCD1,
ALDP) (41). ABCD1 has been proposed to play a crucial role in transport of VLCFA, or
their Coenzyme A (CoA) derivatives, into peroxisomes. This is based on the VLCFA
accumulation and their defective beta oxidation of VLCFA and on the role of the ABCD
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transporter orthologs in the peroxisomal import of fatty acids in yeast (26,54). Recent
studies support this hypothesis as the overexpression of human ABCD1 in Saccaromices
cerevisiae allows the import of several acyl-CoA esters of long chain and VLCFA, such as
C18:1ω9, C16:0, C22:0, and C24:6ω3, into peroxisomes (60).
X-ALD is a complex inherited disease where the same mutation in the ALD gene (ABCD1)
can lead to clinically very distinct phenotypes, a fatal childhood cerebral ALD (cALD) or
the relatively benign adult disease of adrenomyeloneuropathy (AMN) (40,59).
cALD is characterized by progressive cerebral demyelination with a strong inflammatory
response in the white matter leading to neurodegeneration and death often before the patient
reaches adolescence.
AMN affects adults (second to fourth decade) and is characterized by a pure myelopathy and
peripheral neuropathy. The neuropathological hallmark of AMN is an axonopathy
(resembling spastic paraparesis or spastic paraplegia) without significant myelin
degeneration or neuroinflammation. However, about 35% of AMN patients subsequently
develop cerebral demyelination: these patients share the same poor prognosis as children
with cerebral ALD.
Frequently, the different X-ALD phenotypes occur within the same family as a result of an
identical ABCD1 mutation. No phenotype–genotype correlations have been established so
far, which suggests that of modifier genes or environmental/epigenetic/stochastic factors
modulate the clinical outcome of the disease. The molecular events that trigger the transition
from the metabolic phase, which is the accumulation of VLCFA that is already found in
utero, to neuroinflammation and demyelination in the brain in cALD or to axonal
degeneration in spinal cords in AMN are largely unknown. Moreover, many AMN patients
affected by axonal degeneration later develop inflammatory demyelination leading to death
for reasons that remain obscure.
Until recently, the generally held view on the pathogenesis of X-ALD was that the loss of
function of ALD protein (ALDP) causes the accumulation of VLCFA, which would be
incorporated in an anomalous manner into complex lipids such as gangliosides or
phosphatidilcholine (20,57). These structural alterations in the myelin lipidic components
would cause destabilization of myelin sheath and onset of demyelinating pathology. Axonal
degeneration could respond to the same cause because integrity of the cellular membrane is
a prerequisite for myelin–axonal interaction.
However, the X-ALD mouse model, a classical knockout of the ABCD1 gene, do not exhibit
signs of demyelination in spite of accumulation of VLCFA in the brain and the nervous
tissue (16,37). Instead, ABCD1 null mice presents with a late onset neurodegenerative
phenotype with defective motor coordination, locomotor activities and slower nerve
conduction velocity at around 20 months of age. First immunohistochemical evidence of
axonal degeneration and myelin pathology was detectable in the spinal cord after 16 months
of age but not in the brain. Later in life, it was accompanied by microgliosis and astrocytosis
(11,52,53).
The phenotype of ABCD1-deficient mice mimics features of human AMN, thus providing a
model for investigating the pathogenesis of this disease and for evaluation of efficacy of
pharmacological or gene therapeutic approaches (53). The lack of disease progression from
the metabolic abnormalities and axonal degeneration to cerebral demyelination and
neuroinflammation suggest that in addition to loss of ALDP function and VLCFA excess, it
is likely that other factors play a critical role for X-ALD disease expression that differ in a
mouse and a man.
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The Cytotoxicity of VLCFA
The exact mechanism that links the VLCFA excess to axonal degeneration in AMN or to
inflammation and demyelination in cALD remains elusive.
VLCFA are usually found as constituents of complex lipids, such as ganglioside,
phosphatidilcholine and cholesterol ester fractions of brain myelin, and are also found in the
proteolipid protein. In particular, gangliosides and phosphatidilcholine have been proposed
as trigger of the immune response in cerebral ALD. Theda and colleagues had observed
greatest VLCFA excess (16-fold higher) accumulated in the phosphatidilcholine fraction in
intact regions of brain white matter (57). Recently, highest concentration of VLCFA were
also observed in lysophosphatidilcholine (lysoPC) in cALD brain (28). The gangliosides of
an X-ALD brain contain 28% to 50% of fatty acids with chains exceeding 22 carbons (20).
Such VLCFA are absent from gangliosides of control individuals. Of note, immunologic
properties of gangliosides vary with their fatty acid composition, and they have been
implicated in a variety of immunological brain diseases (44).
Studies of VLCFA cytotoxicity using free fatty acids might bring in a limitation for
interpretation of data as the largest pool of fatty acids in the cells are not found free but
complexed to phospholipids and other lipidic species. Secondly, in addition to eliciting an
immune response, this incorporation of VLCFA to complex lipids might destabilize cell
membranes. It is well established that hexacosanoic acid (C26:0) alters the physiological
properties of membranes. Microcalorimetric studies revealed that inclusion of C26:0 in a
model membrane would disrupt its structure (27). Moreover, turnover of C26:0 from
phospholipid membranes is 10 000 times slower than that of long and medium-chain fatty
acids (27). Indeed, the microviscosity of erythrocyte membranes was reported to be
increased in X-ALD patients (35), an abnormality that was replicated in adrenocortical cell
membranes exhibiting increased microviscosity and a decreased Adrenocorticotropic
hormon (ACTH)-stimulated cortisol secretion as a proof of impaired membrane function
(63). Therefore, it is tempting to speculate that similar alterations might be found in the
cellular membranes of neural cells and even of membrane of organelles, thus impairing
essential functions that would contribute to the pathogenesis of AMN and cALD (reviewed
in Powers et al (47)).
Toxicity mechanisms of VLCFA excess were also investigated using various rat primary
neural cell cultures reporting changes in the cellular calcium levels, alterations in
mitochondrial functions and cell death (25). At 20 mmol/L and higher, VLCFA (C22:0.
C24:0 and C26:0) induce cell death of oligodendrocytes and astrocytes. VLCFA induced
increase in intracellular calcium concentrations in oligodendrocytes, being this cell type
more sensitive than astrocytes and neurons. In a similar setting, the mitochondrial membrane
potential was markedly decreased, in particular by C22:0. Mitochondria respiration, in
absence of ADP (state 4) or presence of ADP (active respiration, state 3) was also inhibited.
Consequently, the authors concluded that VLCFA caused cell death by disturbing
mitochondria metabolism and calcium homeostasis. Production of reactive oxygen species
(ROS) was not detected in this system, which used normal cells instead of ABCD1 deficient
cells.
In contrast, a parallel study using human fibroblasts demonstrated that hexacosanoic acid
excess (doses up to 100 uM) generates ROS together with depletion of reduced glutathione
and a decrease in mitochondrial membrane potential in absence of cell death (17).
Disturbance in mitochondria membrane potential seemed common to both types of cultured
cells, neural and fibroblasts. Production of free radicals might lead to oxidative stress when
antioxidant defenses are overwhelmed. As an outcome, oxidation damage of
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macromolecules such as DNA, RNA or proteins lead to detrimental consequences for cell
and organisms. Indeed, incubation of fibroblasts with C26:0 excess generated oxidative
damage to proteins, arising from metal-catalyzed oxidation and glycoxidation/lipoxidation,
as detected with mass spectrometry techniques. This oxidative damage to proteins occurs in
X-ALD fibroblasts but not in control fibroblasts upon C26:0 excess. Moreover, the loss of
ABCD1 gene function also sensitizes fibroblasts to death upon glutathione depletion, in their
culture medium, thus indicating that ABCD1 dysfunction alters oxidative stress homeostasis
(17). The reversal of oxidative lesions caused by VLCFA excess reversed in vitro by vitamin
E offers therapeutic hope as discussed in this symposium (4).
A recent, study has addressed the cytotoxicity of VLCFA complexed to phospholipids in
particular lysophosphatidilcholine (lysoPC C24:0) (12). In this study, Eichler and coworkers
injected lysoPC C24:0 into brain parietal cortex of mice, causing microglial activation and
apoptosis. This toxicity did not occur when lysoPC C16:0 was used, indicating a fatty chain
length dependent cytotoxicity. Of note, the C26:0 content of lysoPC fraction in peripheral
blood is being currently validated as biomarker for the newborn screening of X-ALD (29).
The First Hit: Metabolic Disease of X-ALD and Axonal Degeneration
Underscoring the described in vitro results, evidence of oxidative damage was also
documented in human X-ALD brain: oxidative lesions were found in the form of the lipid
peroxidation product HNE (hidroxy-nonenal) (50). Both AMN and cALD patient had
increased lipid peroxidation (TBA-RS) and decreased tissue nonenzymatic antioxidants
(TAR) (7,61). Recently, damage to proteins has also been reported in peripheral
mononuclear cells from X-ALD patients (19).
Because oxidative stress is involved in a wide variety of neurological disorders, it may be
considered a common event in neurodegenerative pathway that occurs in late stages of the
disease and is simply epiphenomenal or a consequence of tissue damage. Therefore, the use
of antioxidants is being questioned as a valid therapeutic strategy for treating multifactorial
diseases in which multiple and parallel pathways contribute to neurodegeneration, in
Alzheimer disease, Parkinson disease or multiple sclerosis. In X-ALD, however, we have
recently reported evidence suggesting that oxidative stress is an early etiologic factor
contributing to disease pathogenesis in X-ALD mice do not exhibit an overt locomotor
phenotype until 20 months of age in spite of early signs of axonal pathology of APP.
Synaptophysin deposition in axonal swellings of spinal cord can be detected at 15 months of
age along with ultrastructural signs of myelin and axonal damage in peripheral nerves (52).
Recently, we have also observed oxidative damage to proteins and lipids of the same nature,
observed in lesions produced by excess of VLCFA in X-ALD fibroblasts, as an early
biochemical feature of the neurodegenerative cascade in the spinal cord of ABCD1 null
mice at 12 months, prior to disease onset. Interestingly, as early as 3.5 months of age, the
malonaldehyde-lysine (MDAL) marker, a consequence of lipoxidative damage to proteins,
is detected as the most predominant type of lesion to proteins derived from lipid oxidation
adducts (17). Moreover, the degree of VLCFA accumulation parallel the levels of
lipoxidative damage to proteins as recently seen in a double knockout mouse deficient for
both ABCD1 and ABCD2 genes (19,53). It correlates with an earlier disease onset of more
severe neurodegenerative phenotype of the double mutant mice, with axonal damage,
locomotor and behavioral abnormalities and peripheral nerve conduction impairment
(13,53). ABCD1 and ABCD2 share overlapping functions in the beta oxidation of
hexacosanoic acid (13,19) and only double mutants present accumulation of C26:0 in serum
(18). However, ABCD2 seems to have higher affinity to other fatty acid species, such as
C20:0, C22:1ω9 and the precursor of DHA (C24:6ω3) (18,36). Of note, the double mutant
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ABCD1/ABCD2 presents occasionally and at very old ages with inflammatory infiltrates of
T-lymphocytes, a feature absent in ABCD1 or ABCD2 single mutants (53).
In addition to VLCFA abnormality, the functional loss of ABCD1 in X-ALD results in an
additional defective peroxisomal function, the synthesis of plasmalogens (vinyl ether lipids
with antioxidant activity). Accordingly, decreased plasmalogens were reported in X-ALD
patient brains along with increased levels of VLCFA (33,56). Plasmalogen biosynthesis
utilizes acyl-CoA generated by the peroxisomal beta oxidation pathway (23,24).
Presumably, ABCD1 inactivation results in lower amounts of plasmalogens because of lack
of substrates (acyl-CoA). Therefore, metabolic derangements in levels of VLCFA and
plasmalogens might act synergistically in increasing oxidative stress in X-ALD.
As oxidative stress was reported to be directly responsible for axonal degeneration in
cultured primary neurons (15,51) or in vivo in an experimental autoimmune
encephalomyelitis (EAE) model (2), it seems reasonable to propose oxidative burden (direct
consequence of peroxisomal metabolic impairment) as a first hit in the physiopathogenesis
of axonal damage in X-ALD (Figure 1).
The Second Hit: Induction of Inflammatory Phenotype of cALD
The transition from the metabolic disturbance linked to oxidative stress to
neuroinflammatory disease of cALD is driven by the “second hit.” The molecular events
associated with the transition from a relatively benign metabolic disease to a fatal
neuroinflammatory disease in cALD are not well understood at present.
A recent set of data provides some insights into the possible role of ABCD1 dysfunction in
triggering of inflammatory response in glial (astrocytes and C6 glial cells) cells. Studies
using rat primary astrocytes silenced for ABCD1 and/or ABCD2 reported accumulation of
VLCFA, reduced plasmalogens, increased reactive oxygen species production, expression of
enzymes of eicosanoid pathway (5-lipooxygenase, cyclooxygenase-2) and induction of
inflammatory mediators such as cytokines (TNF-alpha, IL-1beta) and inducible nitric oxide
synthase (iNOS) as well as alterations of peroxisomal metabolism (56). The validity of the
relationship between VLCFA accumulation leading to inflammatory response was further
established by down regulation of these changes by reducing the VLCFA load by treatment
with Lorenzo's oil (mixture of oleic and erucic acids). Lorenzo's oil reduces the levels of
VLCFA by competing for enzymes for fatty acid chain elongation. Another study reported
that silencing of ABCD3 gene in C6 glial cell line also induces expression of inflammatory
mediators (8). Astrocytes silenced for ABCD1 and/or ABCD2 and C6 glial cells silenced for
ABCD3 accumulate VLCFA and express proinflammatory mediators suggesting that
dysfunction of those transporters induces proinflammatory signaling pathways in these cell
types. Further, macrophages (65) from ALD mouse and human X-ALD-derived
lymphoblasts (58) were also reported to produce higher levels of inflammatory mediators as
compared to the respective control cells. These studies document that cells induced to
accumulate VLCFA become prone to higher expression and release of inflammatory
mediators. But there are still very many unknowns as similar cell types defective for
ABCD1 function, in ALD mouse brain, do no produce these inflammatory mediators.
In cALD, the inflammation affects the white matter and related cells (45,49). In addition the
neuropathology of cALD is associated with the infiltration of vascular inflammatory
immune cells (22,48) and NO-mediated toxicity as evident from the detection of
nitrotyrosine in the brain of X-ALD patients (21). Myelin breakdown products, as a result of
myelin instability, containing complex lipids and/or acylated proteins enriched in VLCFA
were believed to play a role in this process possibly by inducing CNS resident immune cells
to produce cytokines/chemokines that further upregulate the cellular events to induce myelin
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breakdown (1,10). However, recent studies with ABC peroxisomal transporter (ABCD1 and/
or ABCD2) silenced astrocytes and C6 glial cells silenced for ABCD3 in culture indicate
that metabolic derangements, without myelin degradation products, are sufficient to induce
inflammatory response (56). The observed expression of proinflammatory cytokines such as
TNF-α, IL-1β, and IFN-γ in X-ALD brain indicates a role for these cytokines in
inflammatory demyelination (38,48). Studies using a combination of super gene array, RT-
PCR, and immunohistochemistry techniques have demonstrated the presence of cytokines
(IL-1beta, TNF-alpha, IL-6, IL-2, IL-3, and GM-CF), chemokines (MCP-1, MCP-3,
MIP-1b, SDF-2, fractalkine, eotaxin, MIP-2, MDC, HCC-4), chemokine receptors (CCR-1,
CCR-4, CCR-5) and iNOS in regions of cALD brains such as the demyelinating plaque and
the active edge of the demyelinating plaque compared with histologically unaffected areas
of X-ALD brain and appropriate age-matched control brains (42). Brain tissue in the
inflammatory area had higher levels of proinflammatory cytokines (eg, TNF alpha, IL-1β,
IL-6, IL-2) and chemokines (eg, MCP-1, MCP-3, SDF-2). However, histologically normal-
looking areas of cALD brain when compared with control brain also had increased levels of
proinflammatory cytokines (TNF-alpha, IL-1β, IL-6, IL-2) and chemokines
(CCL-2,4,7,11,16,21 and -22 and CC-1,2,4,5), indicating a relationship between metabolic
abnormality and inflammatory disease in the absence of vascular infiltrates (42).
As suggested by recent studies, the increased oxidative stress/damage (17,50) and reduction
in plasmalogens (5,33) participate in the transition of VLCFA-mediated metabolic disease
into neuroinflammatory disease. These conclusions are supported by the following
observations: (i) loss of ABCD1 function in cultured astrocytes (56) and in the X-ALD
mouse lead to excessive accumulation of VLCFA and increased oxidative stress/damage
(17,46,52); (ii) red blood cells and white matter samples of X-ALD patients contain
decreased levels of plasmalogens (5,33,39,64); (iii) and neither ABCD1 null mice nor mice
deficient in plasmalogen synthesis develop cerebral demyelination whereas the double
mutant do develop microgliosis and moderate myelin abnormalities in CNS (5). These
observations indicate that derangements in VLCFA and plasmalogens induce oxidative
damage leading to expression of lipolytic enzymes and their products (34) followed by
enhanced expression of proinflammatory mediators (33,56). However, interpretation of
studies from mouse mutants lacking plasmalogens deserve some caution as plasmalogen
deficiencies have also been described in other neuroinflammatory disorders. Delineation of
molecular events required for transition of VLCFA-induced oxidative stress/damage into
neuroinflammatory disease is an active area of investigation. Because over 30% of patients
with AMN transition into cerebral ALD, analysis of tissues from these patients may provide
clues to events associated with transition of metabolic disease into the neuroinflammatory
disease of cALD.
The Third Hit: Generalized Loss of Peroxisomal Function and
Neurodegeneration in cALD
The similarities in the neuropathology in the animal model of global peroxisomal
dysfunction in oligodendrocytes (the Pex 5 null mice) compared with the double ABCD1/
Pex 7 null or to the double ABCD1/ABCD2 null mice suggest that generalized loss of
peroxisomal functions may participate in cALD disease pathology (5,30). Pex 5 and Pex 7
(peroxines) as receptors for peroxisome targeted proteins (PTS1 and PTS2), respectively,
play pivotal role in the biogenesis and maintenance of peroxisomes (62).
The inflammatory mediator-induced downregulation of function of peroxisomes in
hepatocytes (3), liver (6), C6 glial cells (31) and CNS of EAE, an animal model of MS (55),
indicate a role for decreased peroxisomes in the pathobiology of neuroinflammatory disease
of cALD. Second, the cytokine-mediated compromised peroxisomal integrity, and impaired
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peroxisomal functions (3,6,32) indicate for overall negative consequences for myelin
synthesis/repair processes. Further, observed higher levels of VLCFA in demyelinating
plaque and demyelinating inflammatory region compared with histologically normal-
looking brain region of cALD brain indicate that peroxisomal functions were altered by the
inflammatory mediators (42). Accordingly, cytokine treatment of cultured cells
compromised the VLCFA β-oxidation and other peroxisomal functions (31,42). Therefore,
possibly the decrease in peroxisomes and peroxisomal functions (eg, VLC fatty acids β-
oxidation, plasmalogen and docosahexaenoic acid biosyntheses) in inflammatory regions of
X-ALD brain will further increase the accumulation of VLCFA (31), thus amplifying the
inflammatory response (production of cytokines) in brain tissues. As expected, the plaque
and inflammatory areas of cALD brain had 2.5- and 3.8-fold greater VLCFA levels
compared with histologically normal-looking areas in cALD brain (31,42). Indeed, studies
from our laboratory using cultured C6 cells demonstrated that cytokine (TNF-alpha, IL-1β,
INF-γ) treatment of these cells negatively affect the metabolism of VLCFA such as
inhibiting their oxidation and thereby accumulation of these fatty acids (31). By using
inhibitors of nitric oxide synthase, NO was identified as one of the intermediates in this
inhibition (9). These observations indicate that in addition to downregulation of
peroxisomes/proteins, the inflammatory mediators (cytokines) induce inactivation of
peroxisomal activities via NO-mediated mechanisms. Further, the downregulation of
peroxisomal proteins/biogenesis under inflammatory disease conditions is supported by the
observed decrease in peroxisomes/protein in the liver of rats treated with sublethal doses of
endotoxin, a Peroxisome proliferator activated receptor alpha (PPARa)-dependent
mechanism (6,43). A sublethal injection of bacterial endotoxin produced drastic changes in
peroxisomal structure and function. Structural changes were characterized by alternation in
membrane lipid composition and hence the fluidity properties (6,32). Changes in function
were associated with a decrease in β-oxidation of VLCFA. Overall, there was a marked
decrease in the population of peroxisomes of normal density (6). These observations indicate
a generalized loss of peroxisomes and thereby their functions in the inflammatory regions of
CNS suggesting that a generalized loss of peroxisomal function participates in X-ALD
neuropathology. Accordingly, mice in which most peroxisome functions are selectively
disrupted by conditional knockout of Pex 5 in oligodendrocytes exhibited not only an
accumulation of VLCFA and deficiency of plasmalogens but also modeled the entire
neuropathological phenotype of human X-ALD including axonal degeneration, cerebral
demyelination and neuroinflammation (30). Recent report showing deficiency of
peroxisomes/peroxisomal dysfunction in neuroinflammatory disease models of EAE,
Krabbe disease and cerebral palsy indicate that in addition to cALD and other peroxisomal
disorders, inflammatory-compromised peroxisomal functions may also participate in the
pathobiologies in these disease conditions (56).
Concluding Remarks
In light of recently generated evidences, we propose a three-hit hypothesis as a framework to
study the disease pathogenesis of X-ALD. The metabolic derangements characterized by
excess of VLCFA and lower plasmalogens levels and oxidative stress (first hit), which in
turn, generates inflammatory disease (second hit) with the participation of environmental,
stochastic, genetic or epigenetic factors. Subsequently, the cytokine and chemokine
mediators (inflammatory response) further cause a generalized loss of peroxisomes/
peroxisomal functions (third hit), creating a vicious circle resulting in cell loss and
progressive inflammatory demyelinating disease. Therefore, therapy for X-ALD
inflammatory disease should also be considered while developing treatment strategies for
the metabolic and oxidative stress disease aspects of X-ALD. Pathophysiological events of
ABCD1 dysfunction may vary in different cell types (eg, astrocytes/microglia vs.
oligodendrocytes vs. neurons) of CNS and are likely to be dependent on the relative
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distribution of peroxisomal ABC transporters and cellular metabolic needs for VLCFA by
different cell types. Elucidation of cell autonomous vs. noncell autonomous mechanisms are
needed to direct future cell therapeutic approaches.
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